

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JD Logistics, Inc.
京东物流股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 2618)

CHANGE OF DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board announces that, with effect from June 28, 2024:

1. Mr. Liming Wang has resigned as an independent non-executive Director, the chairperson of the Remuneration Committee and a member of the Nomination Committee;
2. Dr. Lin Ye has been appointed as an independent non-executive Director, a member of the Remuneration Committee and a member of the Nomination Committee; and
3. Dr. Xiande Zhao has been appointed as the chairperson of the Remuneration Committee.

The board (the “**Board**”) of directors (the “**Directors**”) of JD Logistics, Inc. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) hereby announces the below changes to the Board and the composition of the remuneration committee of the Company (the “**Remuneration Committee**”) and the nomination committee of the Company (the “**Nomination Committee**”).

RESIGNATION OF DIRECTOR

The Board announces that Mr. Liming Wang (王利明) (“**Mr. Wang**”) has tendered his resignation as an independent non-executive Director, the chairperson of the Remuneration Committee and a member of the Nomination Committee, with effect from June 28, 2024 due to his other business engagements which require more of his time and dedication.

Mr. Wang has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude to Mr. Wang for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF DIRECTOR

The Board is pleased to announce that Dr. Lin Ye (葉林) (“**Dr. Ye**”) has been appointed as an independent non-executive Director, a member of the Remuneration Committee and a member of the Nomination Committee, with effect from June 28, 2024.

The biographical details of Dr. Ye are set out below:

Dr. Lin Ye, aged 60, is a doctor of law, a professor and a supervisor of doctoral students of Renmin University of China (中國人民大學) and has over 36 years of experience teaching in the law school of Renmin University of China.

Dr. Ye qualified as a lawyer in China in May 1990. Besides, Dr. Ye has served as independent non-executive director of Capital Securities Co., Ltd. (首創證券股份有限公司) (Shanghai Stock Exchange stock code: 601136) since August 2020, Beijing YJK Building Software Co., Ltd. (北京盈建科軟件股份有限公司) (Shenzhen Stock Exchange stock code: 300935) since September 2023, and Beijing Shougang Co., Ltd. (北京首鋼股份有限公司) (Shenzhen Stock Exchange stock code: 000959) during June 2019 to December 2023. Since June 2020, he has also served as an independent non-executive director of China Life Asset Management Company Limited (中國人壽資產管理有限公司) and China Credit Trust Co., Ltd. (中誠信託有限責任公司).

Further, Dr. Ye is the director of the Rule of Law Research Center in Business Environment (營商環境法治研究中心) of Renmin University of China and the executive director of the Institute of International Commercial Dispute Prevention and Settlement (國際商事爭端預防與解決研究院) of Renmin University of China. Dr. Ye has also served as the vice-chairman of the Commercial Law Society in China Law Society (中國法學會商法學研究會), the vice-chairman of the Civil and Commercial Law Society in Beijing Law Society (北京市法學會民商法學研究會), and the chairman of Beijing Consumer Rights Protection Law Society (北京市消費者權益保護法學會). Dr. Ye’s main research fields include China’s civil law, commercial law, company law, securities law, futures law, contract law, financial services law, consumer protection law, etc. He has published more than 100 papers and more than 10 books in the above relevant fields.

Dr. Ye received his bachelor of law from Renmin University of China in July 1985, and received his master’s degree and doctor’s degree in civil and commercial law from Renmin University of China in July 1987 and July 1993, respectively.

Dr. Ye has entered into an appointment letter with the Company for a term of three years commencing from June 28, 2024 and he will hold office until the next annual general meeting of the Company and will then be eligible for re-election at that meeting, and subject to retirement by rotation and re-election at least once every three years, in accordance with the memorandum and articles of association of the Company and the Corporate Governance Code contained in Appendix C1 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). According to the terms of Dr. Ye’s appointment, Dr. Ye is entitled to an annual director’s fee of RMB340,906 in cash and the equivalent of RMB250,000 of options and/or awards under the rules of the share option scheme or share award scheme adopted by the Company from time to time

and subject to the applicable vesting conditions, and Dr. Ye is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of his duties in connection with the business of the Company. The director's remuneration package was recommended by the Remuneration Committee with reference to Dr. Ye's duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. Ye has confirmed that he does not hold (i) any other position with the Company or other members of the Group; (ii) any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications. Save as disclosed above, as at the date of this announcement, Dr. Ye has confirmed that he does not have any relationship with any Director, senior management or substantial shareholder or controlling shareholders of the Company, or any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Ye has confirmed that (i) he meets the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment. Save as disclosed above, there is no other information that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders or the Stock Exchange relating to Dr. Ye's appointment.

The Board would like to express its warmest welcome to Dr. Ye on his appointment.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that following Mr. Wang's resignation, Dr. Xiande Zhao (趙先德), an independent non-executive Director has been appointed as the chairperson of the Remuneration Committee, and Dr. Ye has been appointed as a member of the Remuneration Committee and a member of the Nomination Committee, with effect from June 28, 2024.

By order of the Board
JD Logistics, Inc.
Mr. Wei Hu
Executive Director

Hong Kong, June 28, 2024

As of the date of this announcement and following the above resignation and appointment of Directors, the Board comprises Mr. Wei Hu as executive Director, Mr. Richard Qiangdong Liu as non-executive Director, and Ms. Nora Gu Yi Wu, Ms. Jennifer Ngar-Wing Yu, Dr. Xiande Zhao, Mr. Yang Zhang and Dr. Lin Ye as independent non-executive Directors.